Management of ulcerative colitis

JM Fell, R Muhammed, C Spray, K Crook… - Archives of disease in …, 2016 - adc.bmj.com
Ulcerative colitis (UC) in children is increasing. The range of treatments available has also
increased too but around 1 in 4 children still require surgery to control their disease. An up …

Resolution of parenteral nutrition–associated jaundice on changing from a soybean oil emulsion to a complex mixed-lipid emulsion

R Muhammed, R Bremner, S Protheroe… - Journal of pediatric …, 2012 - journals.lww.com
Methods: Retrospective cohort comparison examining serum bilirubin during 6 months in
children with PN-associated jaundice who changed to SMOFlipid (n= 8) or remained on …

Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK

R Kapasi, J Glatter, CA Lamb, AG Acheson… - Frontline …, 2020 - fg.bmj.com
Objective Symptoms and clinical course during inflammatory bowel disease (IBD) vary
among individuals. Personalised care is therefore essential to effective management …

Inflammatory bowel disease patient‐reported quality assessment should drive service improvement: a national survey of UK IBD units and patients

AB Hawthorne, J Glatter, J Blackwell… - Alimentary …, 2022 - Wiley Online Library
Background Healthcare service provision in inflammatory bowel disease (IBD) is often
designed to meet targets set by healthcare providers rather than those of patients. It is …

Impact of COVID-19 on diagnosis and management of paediatric inflammatory bowel disease during lockdown: a UK nationwide study

JJ Ashton, J Kammermeier, C Spray… - Archives of disease in …, 2020 - adc.bmj.com
Background COVID-19 has impacted on healthcare provision. Anecdotally, investigations for
children with inflammatory bowel disease (IBD) have been restricted, resulting in diagnosis …

Use of infliximab biosimilar versus originator in a pediatric United Kingdom inflammatory bowel disease induction cohort

N Chanchlani, K Mortier, LJ Williams… - Journal of pediatric …, 2018 - journals.lww.com
Objectives: The aim of the study was to summarize short-term effectiveness, safety, and cost
of using infliximab biosimilar (IFX-B) drugs,(Inflectra [Hospira] and Remsima [NAAP]) …

Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND …

R Hansen, S Meade, RM Beattie, MKH Auth, N Croft… - Gut, 2021 - gut.bmj.com
Objective Paediatric acute severe colitis (ASC) management during the novel SARS-CoV-
2/COVID-19 pandemic is challenging due to reliance on immunosuppression and the …

[HTML][HTML] Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA. 1 and BA. 4/5 variants in patients with inflammatory bowel disease treated with …

Z Liu, K Le, X Zhou, JL Alexander, S Lin… - The Lancet …, 2023 - thelancet.com
Background Anti-TNF drugs, such as infliximab, are associated with attenuated antibody
responses after SARS-CoV-2 vaccination. We aimed to determine how the anti-TNF drug …

Reduced skeletal muscle protein balance in paediatric Crohn's disease

A Davies, A Nixon, R Muhammed, K Tsintzas… - Clinical nutrition, 2020 - Elsevier
Background & aims An inability to respond to nutrition could be implicated in low muscle
mass in Crohn's disease. We aim to determine skeletal muscle metabolic response to …

[HTML][HTML] A double-blind, placebo-controlled trial to assess safety and tolerability of (thetanix) bacteroides thetaiotaomicron in adolescent crohn's disease

R Hansen, IR Sanderson, R Muhammed… - Clinical and …, 2021 - journals.lww.com
METHODS: Subjects who were 16–18 years with Crohn's in remission (weighted pediatric
Crohn's disease activity index< 12.5) were recruited. Each active dose comprised∼ 10 …